In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read MoreIn a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...
Read MoreIn a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreIn a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...
Read MoreIn a nutshell This study aimed to investigate the combination of letrozole and taselisib as a neoadjuvant treatment (before surgery) in patients with hormone receptor-positive, HER2-negative, early stage breast cancer. This study concluded that this treatment...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of OBT076 in patients with advanced breast cancer. The main outcomes will be the frequency of side effects and response to treatment. This trial is recruiting at Columbia University Medical Center, NY, US. The details Breast cancer (BC) is a highly treatable...
Read MoreIn a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...
Read MoreIn a nutshell This study wanted to find out how well patients with hormone-receptor-positive breast cancer survived when treated with ribociclib (Kisqali) added to endocrine therapy. The study found that patients treated with this treatment combination had longer survival compared to endocrine therapy alone. Some background Advanced breast cancer can...
Read MoreIn a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced breast cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...
Read MoreIn a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read More
